140 related articles for article (PubMed ID: 38859683)
1. Tumor treating fields for newly diagnosed high-grade glioma based on the criteria of 2021 WHO CNS5: A retrospective analysis of Chinese patients in a single center.
Zhang L; Ren Y; Peng Y; Luo Y; Liu Y; Wang X; Yang Y; Liu L; Ai P; Yang X; Li Y; Mao Q; Wang F
Cancer Med; 2024 Jun; 13(11):e7350. PubMed ID: 38859683
[TBL] [Abstract][Full Text] [Related]
2. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice.
Shi W; Blumenthal DT; Oberheim Bush NA; Kebir S; Lukas RV; Muragaki Y; Zhu JJ; Glas M
J Neurooncol; 2020 Jul; 148(3):489-500. PubMed ID: 32535723
[TBL] [Abstract][Full Text] [Related]
3. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
[TBL] [Abstract][Full Text] [Related]
4. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort.
She L; Gong X; Su L; Liu C
Front Neurol; 2022; 13():1042888. PubMed ID: 36698900
[TBL] [Abstract][Full Text] [Related]
6. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Toms SA; Kim CY; Nicholas G; Ram Z
J Neurooncol; 2019 Jan; 141(2):467-473. PubMed ID: 30506499
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial.
Ballo MT; Urman N; Lavy-Shahaf G; Grewal J; Bomzon Z; Toms S
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1106-1113. PubMed ID: 31026557
[TBL] [Abstract][Full Text] [Related]
8. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
Lazaridis L; Schäfer N; Teuber-Hanselmann S; Blau T; Schmidt T; Oster C; Weller J; Tzaridis T; Pierscianek D; Keyvani K; Kleinschnitz C; Stuschke M; Scheffler B; Deuschl C; Sure U; Herrlinger U; Kebir S; Glas M
J Cancer Res Clin Oncol; 2020 Mar; 146(3):787-792. PubMed ID: 31828428
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
Ram Z; Kim CY; Hottinger AF; Idbaih A; Nicholas G; Zhu JJ
Front Oncol; 2021; 11():671972. PubMed ID: 34692470
[TBL] [Abstract][Full Text] [Related]
10. Acceptance and compliance of TTFields treatment among high grade glioma patients.
Onken J; Staub-Bartelt F; Vajkoczy P; Misch M
J Neurooncol; 2018 Aug; 139(1):177-184. PubMed ID: 29644485
[TBL] [Abstract][Full Text] [Related]
11. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Burri SH; Gondi V; Brown PD; Mehta MP
Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
[TBL] [Abstract][Full Text] [Related]
13. Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis.
Magouliotis DE; Asprodini EK; Svokos KA; Tasiopoulou VS; Svokos AA; Toms SA
Acta Neurochir (Wien); 2018 Jun; 160(6):1167-1174. PubMed ID: 29696502
[TBL] [Abstract][Full Text] [Related]
14. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study.
Rivera F; Benavides M; Gallego J; Guillen-Ponce C; Lopez-Martin J; Küng M
Pancreatology; 2019 Jan; 19(1):64-72. PubMed ID: 30396819
[TBL] [Abstract][Full Text] [Related]
15. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
16. Effects of time to chemoradiation on high-grade gliomas from the Buenos Aires Metropolitan Area.
Prost DM; Merenzon MA; Gómez-Escalante JI; Primavera A; Vargas Benítez M; Gil AS; Marenco PM; Califano MM; Moughty Cueto C; Zaloff Dakoff JM; Colonna M; Mazzón A; Zaninovich RS; De Cristófaro OR
PLoS One; 2021; 16(4):e0249486. PubMed ID: 33798233
[TBL] [Abstract][Full Text] [Related]
17. Tumor treating fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors.
Wang J; Du Q; Chen J; Liu J; Gu Z; Wang X; Zhang A; Gao S; Shao A; Zhang J; Wang Y
Front Oncol; 2024; 14():1345190. PubMed ID: 38571508
[TBL] [Abstract][Full Text] [Related]
18. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
19. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study.
Bokstein F; Blumenthal D; Limon D; Harosh CB; Ram Z; Grossman R
Front Oncol; 2020; 10():411. PubMed ID: 32373508
[No Abstract] [Full Text] [Related]
[Next] [New Search]